AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03190265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
Study NCT03196635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-Assisted (PA) Breast Compression
Description: The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views CC \& MLO.
Study NCT03196635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technologist-Controlled (TC) Breast Compression
Description: TC compression will be conducted per standard of care practices at the site.
Study NCT01953978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
Study NCT01071005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorelin Depot Bergamo
Description: Lorelin Depot Bergamo, 3,75 mg, single dose.
Study NCT01071005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron Depot - Abbott
Description: Lupron Depot 3,75 mg, single dose.
Study NCT00182767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT00182767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study NCT03663530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meal times
Description: Meal times vary based on the arm: aligned or misaligned
Study NCT02618174 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Control Condition
Description: Message about age of University of Birmingham
Study NCT02618174 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Food-based Control Condition
Description: Message about variety of vegetables in the world
Study NCT02618174 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Condition
Description: Message about the health benefits of eating vegetables
Study NCT02618174 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Descriptive Social Norm
Description: Message suggesting most people eat plenty of vegetables
Study NCT02618174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liking Social Norm
Description: Message suggesting most people like eating vegetables
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen IV/PO
Description: Acetaminophen 1g IV/PO every 6 hours
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen PO
Description: Acetaminophen 1g PO every 6 hours
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Ketorolac 30mg IV once
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Description: Celebrex 200mg PO every 12 hours
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg PO every 12 hours
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 100mg PO every 6 hours
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 100mg PO every 8 hours
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 300mg PO every 8 hours
Study NCT01524497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
Study NCT04373772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal massage
Description: the patients in the AM group were given a total of 30 minutes of AM by the nurses (HD, OM) everyday for 15 minutes in the morning and evening.In this study AM, which included effleurage, strokes, petrissage and vibration techniques, was applied to the patients for 15 minutes in each session at 9:00 am and 9:00 pm.
Study NCT01953978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
Study NCT01953978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
Study NCT01953978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
Study NCT01953978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
Study NCT01953978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zofran
Description: Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
Study NCT01953978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
Study NCT01953978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
Study NCT01953978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
Study NCT01953978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
Study NCT00124124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH; Peptides; Dendritic Cells
Description: Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
Study NCT00124124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH, peptides plus Montanide
Description: Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
Study NCT01862484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Restricted Diet
Description: Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
Study NCT01862484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Ruse Diet
Description: Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
Study NCT00805961 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
Study NCT00805961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
Study NCT00805961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
Study NCT00805961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
Study NCT03663530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal times
Description: Meal times vary based on the arm: aligned or misaligned
Study NCT04140955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tapering plan and telephone counselling
Description: Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
Study NCT01659281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: 6 mg/kg/day for 2 days (total dose 12 mg/kg)
Study NCT01659281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: 4 mg/kg/day for 3 days
Study NCT01659281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine
Description: 15mg/kg at T=0 and 10 mg/kg 6-24 hours later
Study NCT01659281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine
Description: 8 mg/kg daily for 3 days
Study NCT00747344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Controlled Period (CP)
Description: Placebo, Weeks 0-12
Study NCT00747344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg - CP
Description: Ustekinumab 45 mg, Weeks 0-12
Study NCT00747344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ustekinumab 45 mg - after CP
Description: Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
Study NCT00747344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg - after CP
Description: Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
Study NCT00989235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: IV solution, IV, 10 mg/Kg, Once monthly, 1 year
Study NCT00989235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: IV solution, IV, 5 mg/Kg, Once monthly, 1 year
Study NCT02986243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 months worth of exercise regimen
Study NCT02986243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet Plan
Description: Each subject will receive a personalized diet plan from nutritionist.
Study NCT01844011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily electronic reminders
Description: Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
Study NCT01201616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Low Carbohydrate Diet
Description: 55% total energy intake from fats, 17% from protein and 28% from carbohydrate
Study NCT01201616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat High Carbohydrate Diet
Description: 20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
Study NCT01514240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D9421-C capsule 3 mg
Description: Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
Study NCT01514240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine tablets
Description: Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
Study NCT03095586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin
Study NCT03095586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study NCT02615405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 \& 2.
Study NCT02615405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 \& 2.
Study NCT02615405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
Study NCT05207332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHO+PRO
Description: A vegan product containing carbohydrate and protein
Study NCT05207332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CHO
Description: containing carbohydrate
Study NCT02823184 — intervention group
Intervention type: BIOLOGICAL
Intervention: RNA sample of total leukocytes before start of treatment
Description: RNA sample of total leukocytes before start of treatment
Study NCT02594098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
Study NCT02594098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
Study NCT01657136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: comparison of different drugs
Study NCT01657136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker
Description: comparison of different drugs
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine patch every 12 hours
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)
Study NCT03472469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia
Description: Regional anesthesia
Study NCT02661542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01
Study NCT03730493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.
Description: In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
Study NCT03392805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: beginning of regular physical activity under the supervision of a coach
Study NCT03960359 — intervention group
Intervention type: OTHER
Intervention: Clinical, microbiological and inflammatory phenotype
Description: Clinical phenotype: temporal pattern of wheeze (EVW, SIW, MTW), history and clinical data, allergy diagnosis work-up Microbiological phenotype: viral status (PCR in nasal swab sample), bacteriological status (culture of induced sputum) Inflammatory phenotype: profile of cytokines, phenotype of immune cells in the blood and the sputum, cytokine response to TLR ligands by peripheral blood mononuclear cells.
Study NCT02841449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypohydrated
Description: Participants remain hypohydrated after the heat tent procedure
Study NCT02841449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehydrated
Description: Participants rehydrate after the heat tent procedure
Study NCT02159352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT02159352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Study NCT02159352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02159352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Study NCT01604824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: SC injection in the abdomen
Study NCT01604824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection in the abdomen
Study NCT00805961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10mg by mouth daily, beginning Week 11
Study NCT04546880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During the diaphragmatic breathing, attention is focused on the correct abdominal breathing.~The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over breathing.
Study NCT04546880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercises
Description: Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability.
Study NCT04546880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization exercises
Description: Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability.
Study NCT04539652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Experimental group are treated with TenofoBell®
Study NCT02655705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: Male 200 mg/day, Female 150 mg/day for 16 weeks
Study NCT02655705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
Study NCT02132793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anger Management Therapy
Description: Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.